Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, USA.
Expert Opin Pharmacother. 2020 Jan;21(1):39-45. doi: 10.1080/14656566.2019.1685499. Epub 2019 Oct 30.
: Reduction of intraocular pressure (IOP) is the only known modifiable risk factor for prevention and treatment of glaucoma. Rho-kinase (ROCK) inhibitors are a new class of glaucoma medications introduced recently with novel mechanisms of action and favorable safety profiles. Latanoprost, a common first line drug used for treatment of glaucoma, does not adequately control pressures in all cases. Addition of more than one anti-glaucoma medication affects patient compliance and adherence. Fixed-combination eye drops are combinations of two or more active drugs in a single dosage form, thus simplify dosing. New to this group is the fixed combination netarsudil- latanoprost (FCNL).: This review focuses on FCNL, its pharmacodynamics and pharmacokinetics. It also details the efficacy and safety of individual drugs compared to FCNL.: The combination of latanoprost and netarsudil is a potent medication and modulates all known targets for IOP reduction in a single drop and has been shown to be more effective than either drug alone. FCNL is an alternative for those with inadequately controlled IOP on a prostaglandin analog alone, as well as those for whom a simplified regimen is desirable, or those who are not good candidates for other classes of glaucoma medications.
降低眼内压（IOP）是预防和治疗青光眼的唯一已知可改变的危险因素。Rho 激酶（ROCK）抑制剂是最近引入的一类新型青光眼药物，具有新颖的作用机制和良好的安全性特征。拉坦前列素，一种常用于治疗青光眼的一线药物，不能在所有情况下充分控制眼压。添加一种以上的抗青光眼药物会影响患者的依从性和顺应性。固定剂量滴眼液是两种或多种活性药物在单一剂量形式中的组合，因此简化了给药。该组的新成员是那他珠单抗-拉坦前列素（FCNL）。本文重点介绍了 FCNL 的药代动力学和药效学。它还详细介绍了与 FCNL 相比，单独药物的疗效和安全性。拉坦前列素和那他珠单抗的联合使用是一种有效的药物，可以在一滴眼药水下调节所有已知的眼压降低靶点，并且已被证明比单独使用任何一种药物都更有效。对于那些单独使用前列腺素类似物不能充分控制眼压的患者，以及那些希望简化治疗方案的患者，或者那些不适合其他类别的青光眼药物的患者，FCNL 是一种替代选择。
